Loading...

Industry News

SynBioBeta brings you the latest news weekly to help you stay informed and learn about the latest developments in the synthetic biology industry. Subscribe to receive the latest news weekly to your inbox. Have news to share? Contact us to submit your story.

Subscribe

Stay Updated on the Latest News in Synthetic Biology

Subscribe to the Weekly SynBioBeta Digest
Subscribe

Latest News

March 2017

Evolva teams up with FCI to expand nootkatone and valencene sales & marketing in Europe

Thermo Fisher Scientific Announces First-Ever Cloud-Based Application for Connectivity to Electronic Pipettes

Synpromics Granted Key Patent in Synthetic Promoter Development

Eurofins Genomics US Announces Commercial Launch of Next Generation DNA Synthesis Service

BioBright Tools Bring ‘Superpowers’ to the Biology Lab

Lord David Prior of Brampton to Keynote SynBioBeta London

The Tools, Challenges, and Future Uses for Renewable Bio-based Materials

Allergan and Editas Medicine Enter into Strategic R&D Alliance to Discover and Develop CRISPR Genome Editing Medicines for Eye Diseases

CRISPR Therapeutics and Casebia Therapeutics Announce Commercial License Agreement With MaxCyte

Intrexon Creates Precigen, Inc. and Accelerates Strategic Review of Structural Options Related to Health Assets

Horizon Discovery enters into R&D and licensing partnership with Amplycell S.A. for bioproduction cell line optimisation

Annual Synthetic Biology Industry Investment Update Over $1 Billion USD Invested in Past 12 Months

Bolt Threads Brings a Glimpse of the Future of Advanced Materials to SXSW

Drew Endy to Keynote SynBioBeta London

Federal Regulatory Agencies Need to Prepare for Greater Quantity and Range of Biotechnology Products

Researchers Assemble Five New Synthetic Yeast Chromosomes

Molecular Assemblies Appoints Floyd E. Romesberg from The Scripps Research Institute to Scientific Advisory Board

Evolva achieves second milestone in fragrance & flavour alliance with Takasago

Intellia Therapeutics Demonstrates Pioneering CRISPR/Cas9 Genome Editing Efficiency Data Using Lipid Nanoparticle Delivery Technology

Kite Pharma’s Engineered T-Cell Therapies for Cancers Delivers Astonishing Results